168 related articles for article (PubMed ID: 34253166)
1. Downregulation of NKG2DLs by TGF-β in human lung cancer cells.
Lee YS; Choi H; Cho HR; Son WC; Park YS; Kang CD; Bae J
BMC Immunol; 2021 Jul; 22(1):44. PubMed ID: 34253166
[TBL] [Abstract][Full Text] [Related]
2. Radiation-induced matrix metalloproteinases limit natural killer cell-mediated anticancer immunity in NCI-H23 lung cancer cells.
Heo W; Lee YS; Son CH; Yang K; Park YS; Bae J
Mol Med Rep; 2015 Mar; 11(3):1800-6. PubMed ID: 25385045
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway.
Le Maux Chansac B; Missé D; Richon C; Vergnon I; Kubin M; Soria JC; Moretta A; Chouaib S; Mami-Chouaib F
Int Immunol; 2008 Jul; 20(7):801-10. PubMed ID: 18441340
[TBL] [Abstract][Full Text] [Related]
4. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
5. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.
Lee JC; Lee KM; Kim DW; Heo DS
J Immunol; 2004 Jun; 172(12):7335-40. PubMed ID: 15187109
[TBL] [Abstract][Full Text] [Related]
6. EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
Kim H; Kim SH; Kim MJ; Kim SJ; Park SJ; Chung JS; Bae JH; Kang CD
J Immunother; 2011 May; 34(4):372-81. PubMed ID: 21499124
[TBL] [Abstract][Full Text] [Related]
7. The TGF-β-induced up-regulation of NKG2DLs requires AKT/GSK-3β-mediated stabilization of SP1.
Chen XH; Lu LL; Ke HP; Liu ZC; Wang HF; Wei W; Qi YF; Wang HS; Cai SH; Du J
J Cell Mol Med; 2017 May; 21(5):860-870. PubMed ID: 28165192
[TBL] [Abstract][Full Text] [Related]
8. c-Cbl regulates MICA- but not ULBP2-induced NKG2D down-modulation in human NK cells.
Molfetta R; Quatrini L; Capuano C; Gasparrini F; Zitti B; Zingoni A; Galandrini R; Santoni A; Paolini R
Eur J Immunol; 2014 Sep; 44(9):2761-70. PubMed ID: 24846123
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
Maier A; Peille AL; Vuaroqueaux V; Lahn M
Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models.
Otegbeye F; Ojo E; Moreton S; Mackowski N; Lee DA; de Lima M; Wald DN
PLoS One; 2018; 13(1):e0191358. PubMed ID: 29342200
[TBL] [Abstract][Full Text] [Related]
11. Leveraging NKG2D Ligands in Immuno-Oncology.
Fuertes MB; Domaica CI; Zwirner NW
Front Immunol; 2021; 12():713158. PubMed ID: 34394116
[TBL] [Abstract][Full Text] [Related]
12. Blocking transforming growth factor-β signaling pathway augments antitumor effect of adoptive NK-92 cell therapy.
Yang B; Liu H; Shi W; Wang Z; Sun S; Zhang G; Hu Y; Liu T; Jiao S
Int Immunopharmacol; 2013 Oct; 17(2):198-204. PubMed ID: 23806302
[TBL] [Abstract][Full Text] [Related]
13. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
14. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
15. Boosting Natural Killer Cell-Based Cancer Immunotherapy with Selenocystine/Transforming Growth Factor-Beta Inhibitor-Encapsulated Nanoemulsion.
Liu C; Lai H; Chen T
ACS Nano; 2020 Sep; 14(9):11067-11082. PubMed ID: 32806028
[TBL] [Abstract][Full Text] [Related]
16. Release of Soluble Ligands for the Activating NKG2D Receptor: One More Immune Evasion Strategy Evolved by HIV-1 ?
Giuliani E; Vassena L; Cerboni C; Doria M
Curr Drug Targets; 2016; 17(1):54-64. PubMed ID: 26122035
[TBL] [Abstract][Full Text] [Related]
17. Antigen-activated human T lymphocytes express cell-surface NKG2D ligands via an ATM/ATR-dependent mechanism and become susceptible to autologous NK- cell lysis.
Cerboni C; Zingoni A; Cippitelli M; Piccoli M; Frati L; Santoni A
Blood; 2007 Jul; 110(2):606-15. PubMed ID: 17405908
[TBL] [Abstract][Full Text] [Related]
18. Altered NK-cell compartment and dysfunctional NKG2D/NKG2D-ligand axis in patients with ataxia-telangiectasia.
Desimio MG; Finocchi A; Di Matteo G; Di Cesare S; Giancotta C; Conti F; Chessa L; Piane M; Montin D; Dellepiane M; Rossi P; Cancrini C; Doria M
Clin Immunol; 2021 Sep; 230():108802. PubMed ID: 34298181
[TBL] [Abstract][Full Text] [Related]
19. Human tumour immune evasion via TGF-β blocks NK cell activation but not survival allowing therapeutic restoration of anti-tumour activity.
Wilson EB; El-Jawhari JJ; Neilson AL; Hall GD; Melcher AA; Meade JL; Cook GP
PLoS One; 2011; 6(9):e22842. PubMed ID: 21909397
[TBL] [Abstract][Full Text] [Related]
20. 5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands.
Zhao L; Wang WJ; Zhang JN; Zhang XY
Asian Pac J Cancer Prev; 2014; 15(9):4039-44. PubMed ID: 24935593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
